Monopar Therapeutics Inc（MNPR）の財務MNPRMonopar Therapeutics Inc

Evaluating the bottom line, Monopar Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -19.50%, provide a clear picture of how effectively MNPR converts its operational activities into shareholder value.

In the context of the broader market, MNPR competes directly with industry leaders such as CBIO and NGNE. With a market capitalization of $562.35M, it holds a leading position in the sector. When comparing efficiency, MNPR's gross margin of N/A stands against CBIO's 100.00% and NGNE's N/A. Such benchmarking helps identify whether Monopar Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

The company has consistently reported negative net income, with Q2 2026 showing a loss of -5,313,300 USD and an EPS of -0.62, reflecting ongoing financial struggles.